<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-10-30" updated="2019-12-02">
  <drugbank-id primary="true">DB09293</drugbank-id>
  <drugbank-id>DB12217</drugbank-id>
  <name>Iodide I-131</name>
  <description>Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy.  Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation dose is via gamma radiation, while the other 90% (beta radiation) causes tissue damage without contributing to any ability to see or image the isotope. Low levels of beta radiation are also known for causing cancer as this dose is highly mutagenic. For this reason, less toxic iodine isotopes such as I-123 are more frequently used in nuclear imaging, while I-131 is reserved for its tissue destroying effects. Because the thyroid gland naturally takes up iodine from the body, therapeutic methods using radioisotopes can take advantage of this mechanism for localization of drug to the site of malignancy. &#13;
&#13;
Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine.  Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine.  It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function.</description>
  <cas-number>14914-30-8</cas-number>
  <unii>4GC1FOQ22U</unii>
  <average-mass>130.9067</average-mass>
  <monoisotopic-mass>130.906672748</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine.  Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine.  It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function.</indication>
  <pharmacodynamics>The therapeutic effects of sodium iodide I-131 are a result of the ionizing radiation absorbed by the thyroidal tissue.  Tissue damage is the result of direct insult to molecules by ionization and excitation and the consequent dissociation of those molecules.  About 90% of local irradiation from sodium iodide I-131 is the result of beta radiation and 10% is the result of gamma radiation. </pharmacodynamics>
  <mechanism-of-action>Taken orally, sodium iodide I-131 is rapidly absorbed and distributed within the extracellular fluid of the body.  The iodide is concentrated in the thyroid via the sodium/iodide symporter, and subsequently oxidized to iodine.  The destruction of thyroidal tissue is achieved by the beta emission of sodium iodide I-131. </mechanism-of-action>
  <toxicity>Adverse reactions that have been reported with doses of sodium iodide I-131 used in the treatment of benign disease include sialadenitis, chest pain, tachycardia, iododerma, itching skin, rash, hives, hypothyroidism, hyperthyroidism, thyrotoxic crisis, hypoparathyroidism, and local swelling. &#13;
Adverse reactions that have been reported with doses of sodium iodide I-131 used in the treatment of malignant disease include radiation sickness, bone marrow depression, anemia, leucopenia, thrombocytopenia, blood dyscrasia, leukemia, solid cancers, lacrimal gland dysfunction, salivary gland dysfunction, congenital hypothyroidism, chromosomal abnormalities, cerebral edema, radiation pneumonitis, and pulmonary fibrosis.</toxicity>
  <metabolism>Trapped iodide is oxidized to iodine and organically incorporated so rapidly that the iodide trap of the thyroid contains less than 0.2 % free iodide in comparison to the organically bound iodine.  This process results in further concentration of iodine in the thyroid gland to about 500 times that in the blood. </metabolism>
  <absorption>After oral administration, sodium iodide I-131 is absorbed rapidly from the upper gastrointestinal tract (90% in 60 minutes). Following absorption, the iodide is primarily distributed within the extra-cellular fluid of the body.  It is trapped by the thyroid.  The thyroid uptake of iodide is usually increased in hyperthyroidism and in goiter with impaired hormone synthesis, decreased in hypothyroidism, and normal to decreased in hypothyroidism receiving iodine.  It should be noted that the uptake of radioactive iodide is a function of stable iodide concentration in the serum and the functional state of the thyroid.</absorption>
  <half-life>Iodine I-131 decays by beta emission and associated gamma emission with a physical half-life of 8.04 days.</half-life>
  <protein-binding>Sodium Iodide I-131 is not protein bound.</protein-binding>
  <route-of-elimination>Sodium Iodide I-131 is excreted by the kidneys.  The normal range of urinary excretion is 37 to 75 % of the administered dose, varying with the thyroid and renal function of the patient.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of inorganic compounds known as homogeneous halogens. These are inorganic non-metallic compounds in which the largest atom is a nobel gas.</description>
    <direct-parent>Homogeneous halogens</direct-parent>
    <kingdom>Inorganic compounds</kingdom>
    <superclass>Homogeneous non-metal compounds</superclass>
    <class>Homogeneous halogens</class>
    <subclass/>
    <substituent>Homogeneous halogen</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002460</drugbank-id>
      <name>Sodium iodide I-131</name>
      <unii>29VCO8ACHH</unii>
      <cas-number>7790-26-3</cas-number>
      <inchikey>FVAUCKIRQBBSSJ-LAIFMVDKSA-M</inchikey>
      <average-mass>153.8959</average-mass>
      <monoisotopic-mass>153.89589345</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Iodide I-131</synonym>
    <synonym language="english" coder="">Iodide I-131 ion</synonym>
    <synonym language="english" coder="">Iodide ion I 131</synonym>
    <synonym language="english" coder="">Iodide ion, I-131</synonym>
    <synonym language="english" coder="">Iodide-131</synonym>
    <synonym language="english" coder="">iodine I-131</synonym>
    <synonym language="english" coder="">Radioiodine</synonym>
  </synonyms>
  <products>
    <product>
      <name>Hicon</name>
      <labeller>Jubilant Draximage Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>65174-880</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mCi/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA021305</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>I 131 Mini</name>
      <labeller>Anazao Health Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>51808-119</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>500 mCi/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>I3odine MAXTM</name>
      <labeller>International Isotopes Inc</labeller>
      <ndc-id/>
      <ndc-product-code>69208-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-01-01</started-marketing-on>
      <ended-marketing-on>2016-10-25</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>3500 mCi/1mL</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Iodotope</name>
      <labeller>Bracco Diagnostics, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0270-0072</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1957-06-14</started-marketing-on>
      <ended-marketing-on>2008-06-19</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>130 mCi/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA010929</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Iodide I 131</name>
      <labeller>Mallinckrodt</labeller>
      <ndc-id/>
      <ndc-product-code>0019-9452</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-25</started-marketing-on>
      <ended-marketing-on>2017-07-01</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>1 mCi/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA016517</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Iodide I 131</name>
      <labeller>Mallinckrodt Nuclear Medicine Llc</labeller>
      <ndc-id/>
      <ndc-product-code>69945-452</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-27</started-marketing-on>
      <ended-marketing-on>2018-07-02</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>1 mCi/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA016517</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Iodide I 131 Diagnostic</name>
      <labeller>Jubilant Draximage Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>65174-461</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mCi/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021305</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Iodide I 131 Therapeutic</name>
      <labeller>Jubilant Draximage Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>65174-441</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-01</started-marketing-on>
      <ended-marketing-on>2012-02-07</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>200 mCi/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021305</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Iodide I-131</name>
      <labeller>International Isotopes Inc</labeller>
      <ndc-id/>
      <ndc-product-code>69208-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution, concentrate</dosage-form>
      <strength>3500 mCi/1mL</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Iodide I-131 Therapeutic</name>
      <labeller>Mallinckrodt Nuclear Medicine Llc</labeller>
      <ndc-id/>
      <ndc-product-code>69945-450</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-27</started-marketing-on>
      <ended-marketing-on>2018-07-02</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>5 mCi/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA016515</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Iodide I-131 Therapeutic</name>
      <labeller>Mallinckrodt Nuclear Medicine Llc</labeller>
      <ndc-id/>
      <ndc-product-code>69945-451</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-27</started-marketing-on>
      <ended-marketing-on>2018-07-02</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>25 mCi/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA016515</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Iodide I-131 Therapeutic</name>
      <labeller>Mallinckrodt</labeller>
      <ndc-id/>
      <ndc-product-code>0019-9450</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-22</started-marketing-on>
      <ended-marketing-on>2017-07-01</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>5 mCi/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA016515</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Iodide I-131 Therapeutic</name>
      <labeller>Mallinckrodt</labeller>
      <ndc-id/>
      <ndc-product-code>0019-9451</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-22</started-marketing-on>
      <ended-marketing-on>2017-07-01</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>25 mCi/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA016515</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Sodium Iodide I 131 Therapeutic</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
    <mixture>
      <name>I 131 Mini</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
    <mixture>
      <name>Iodotope</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Iodide I 131</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Iodide I-131 Therapeutic</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Iodide I-131 Therapeutic</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
    <mixture>
      <name>Hicon</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
    <mixture>
      <name>I3odine MAXTM</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Iodide I 131</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Iodide I-131 Therapeutic</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Iodide I-131 Therapeutic</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Iodide I-131</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Iodide I 131 Diagnostic</name>
      <ingredients>Iodide I-131</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Diagnostic Radiopharmaceuticals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Iodine (131I) Compounds</category>
      <mesh-id/>
    </category>
    <category>
      <category>Radioactive Therapeutic Agent</category>
      <mesh-id/>
    </category>
    <category>
      <category>Radiopharmaceutical Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Therapeutic Radiopharmaceuticals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Thyroid Diagnostic Radiopharmaceuticals</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>1 mCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>500 mCi/1</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>3500 mCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength>130 mCi/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength>1 mCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>100 mCi/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>200 mCi/1</strength>
    </dosage>
    <dosage>
      <form>Solution, concentrate</form>
      <route>Oral</route>
      <strength>3500 mCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>25 mCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>5 mCi/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V09FX03">
      <level code="V09FX">Various thyroid diagnostic radiopharmaceuticals</level>
      <level code="V09F">THYROID</level>
      <level code="V09">DIAGNOSTIC RADIOPHARMACEUTICALS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
    <atc-code code="V10XA01">
      <level code="V10XA">Iodine (131I) compounds</level>
      <level code="V10X">OTHER THERAPEUTIC RADIOPHARMACEUTICALS</level>
      <level code="V10">THERAPEUTIC RADIOPHARMACEUTICALS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09293.pdf?1472663994</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Carbimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Propylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03374</drugbank-id>
      <name>3,5-Diiodotyrosine</name>
      <description>The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with 3,5-Diiodotyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06715</drugbank-id>
      <name>Potassium Iodide</name>
      <description>The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Potassium Iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07637</drugbank-id>
      <name>Dibromotyrosine</name>
      <description>The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Dibromotyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Potassium perchlorate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13644</drugbank-id>
      <name>Methylthiouracil</name>
      <description>The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Methylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13804</drugbank-id>
      <name>Benzylthiouracil</name>
      <description>The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Benzylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>Amiodarone may decrease effectiveness of Iodide I-131 as a diagnostic agent.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.02</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(131I)iodide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(131I)iodide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>130.9067</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>130.906672748</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[131I-]</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>I</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/HI/h1H/p-1/i1+4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>XMBWDFGMSWQBCA-RNFDNDRNSA-M</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>13.95</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>5.07</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>-9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>167195</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>310265185</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D02259</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>146281</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Iodine-131</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201084</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/sodium-iodide-i-131-drug/indications-dosage.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>https://www.drugs.com/pro/sodium-iodide-i-131.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>